Breast Cancer‐Derived Exosomes Reflect the Cell‐of‐Origin Phenotype

Wen, Shu; Lima, Luize Gonçalves; Lobb, Richard J.; Norris, Emma L.; Hastie, Marcus L.; Krumeich, Sophie; Möller, Andreas

doi:10.1002/pmic.201800180

Cited by 89 publications

(72 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, various exosome-isolation strategies have been developed. The most promising of these methods for a deep molecular characterization of intra-tumor cell communication encompass the immune-selective enrichments of tumor antigens (15,18). These tools, which act synergistically with innovative molecular biology techniques such as next generation sequencing and dPcR, may improve the accuracy and sensitivity of exosomes analysis (45,46).…”

Section: Discussionmentioning

confidence: 99%

“…This is grounded in the evidence that exosomes released by tumor cells present specific and pan-cancer antigens at the membrane surface (14)(15)(16), enabling the possibility to determine the nature of the cell of origin, and to isolate the exosome fraction using the appropriate antibodies. Exosome enrichment has already been explored in the solid tumors field, with successful results (17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

due to the discovery of their role in intra-cellular communications, exosomes, which carry information specific to the cell of origin, have garnered considerable attention in cancer research. Moreover, there is evidence to suggest the possibility of isolating different exosome sub-populations based on target antigens at the cell surface. Philadelphia chromosome-positive (Ph +) chronic myeloid leukemia (cML) is a clonal myeloproliferative neoplasia characterized by the breakpoint cluster region-proto-oncogene 1 tyrosine-protein kinase (BcR-ABL1) fusion-gene, derived from the t (9;22) translocation. Tyrosine kinase inhibitors (TKIs) target BcR-ABL1 protein and induce major or deep molecular responses in the majority of patients. despite the fact that several studies have demonstrated the persistence of leukemic cells in the bone marrow niche, even following treatment, TKIs prolong patient survival time and facilitate treatment-free remission. These characteristics render cML a plausible model for investigating the feasibility of tumor-derived exosome fraction enrichment. In the present study, patients in the chronic phase (cP) of CML were treated with TKIs, and the quantification of the BCR-ABL1 exosomal transcript was performed using digital PcR (dPcR). The possibility of tumor-derived exosomes enrichment was confirmed, and for the first time, to the best of our knowledge, the detection of the BcR-ABL1 transcript highlighted the presence of active leukemic cells in patients with CP-CML. According to these findings, tumor-derived exosomes may be considered a novel tool for the identification of active leukemic cells, and for the assessment of innovative monitoring focused on the biological functions of exosomes in cML.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Proteomic analyses of EVs have revealed heterogeneity in exosomal markers, highlighting the usefulness of this heterogeneity in experimental studies based on marker-dependent purification methods [ 25 ]. The source of exosomes can also influence their heterogeneity, and exosomes derived from different tissue types or organs possess different biological activities, and this feature also applies to cancer cell-derived exosomes [ 108 ]. It has been demonstrated that exosomal production by cancer tissue is much higher compared with that of non-cancer tissue close to the carcinoma.…”

Section: Characteristics Of Exosomes In Cancermentioning

confidence: 99%

Isolation and characterization of exosomes for cancer research

et al. 2020

View full text Add to dashboard Cite

Exosomes are a subset of extracellular vesicles that carry specific combinations of proteins, nucleic acids, metabolites, and lipids. Mounting evidence suggests that exosomes participate in intercellular communication and act as important molecular vehicles in the regulation of numerous physiological and pathological processes, including cancer development. Exosomes are released by various cell types under both normal and pathological conditions, and they can be found in multiple bodily fluids. Moreover, exosomes carrying a wide variety of important macromolecules provide a window into altered cellular or tissue states. Their presence in biological fluids renders them an attractive, minimally invasive approach for liquid biopsies with potential biomarkers for cancer diagnosis, prediction, and surveillance. Due to their biocompatibility and low immunogenicity and cytotoxicity, exosomes have potential clinical applications in the development of innovative therapeutic approaches. Here, we summarize recent advances in various technologies for exosome isolation for cancer research. We outline the functions of exosomes in regulating tumor metastasis, drug resistance, and immune modulation in the context of cancer development. Finally, we discuss prospects and challenges for the clinical development of exosome-based liquid biopsies and therapeutics.

show abstract

“…Recent data involving proteomic assessment demonstrated that the protein cargo of exosomes reflects the epithelial / mesenchymal phenotype of secreting breast cancer cells. Thus, breast cancer phenotypes may be differentiated based on their protein content carried by exosomes [37].…”

Section: Emt Proteomicsmentioning

confidence: 99%

Proteomic Technology “Lens” for Epithelial-Mesenchymal Transition Process Identification in Oncology

Neagu

Constantin

Bostan

et al. 2019

Analytical Cellular Pathology

View full text Add to dashboard Cite

The epithelial-mesenchymal transition (EMT) is a complex transformation process that induces local and distant progression of many malignant tumours. Due to its complex array of proteins that are dynamically over-/underexpressed during this process, proteomic technologies gained their place in the EMT research in the last years. Proteomics has identified new molecular pathways of this process and brought important insights to develop new therapy targets. Various proteomic tools and multiple combinations were developed in this area. Out of the proteomic technology armentarium, mass spectrometry and array technologies are the most used approaches. The main characteristics of the proteomic technology used in this domain are high throughput and detection of minute concentration in small samples. We present herein, using various proteomic technologies, the identification in cancer cell lines and in tumour tissue EMT-related proteins, proteins that are involved in the activation of different cellular pathways. Proteomics has brought besides standard EMT markers (e.g., cell-cell adhesion proteins and transcription factors) other future potential markers for improving diagnosis, monitoring evolution, and developing new therapy targets. Future will increase the proteomic role in clinical investigation and validation of EMT-related biomarkers.

show abstract

Breast Cancer‐Derived Exosomes Reflect the Cell‐of‐Origin Phenotype

Cited by 89 publications

References 51 publications

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

Isolation and characterization of exosomes for cancer research

Proteomic Technology “Lens” for Epithelial-Mesenchymal Transition Process Identification in Oncology

Contact Info

Product

Resources

About